(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Taiho Oncology, Inc.
Cancer Research UK
M.D. Anderson Cancer Center
Geron Corporation
Cancer Research UK